AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05569031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: patients with tramadol abuse will use lofixidine for 10 days.
Study NCT01006473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Study NCT04866251 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gag reflex test; assessment of Mallampati Score
Description: Testing of gag reflex Assessment of Mallampati Score
Study NCT01009580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
Study NCT01009580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
Study NCT04754204 — intervention group
Intervention type: DEVICE
Intervention: Arrhythmia Management System (AMS)
Description: AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity and body posture.
Study NCT03187574 — intervention group
Intervention type: DEVICE
Intervention: Elevate Ant™
Description: Surgery with Elevate Ant™
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or by subcutaneous injection (SQ).
Study NCT03187574 — intervention group
Intervention type: DEVICE
Intervention: Perigee™
Description: Surgery with Perigee™
Study NCT02087709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Study NCT02715791 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAP-HC-DM
Description: Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.~Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.~Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.~Clinicians will see and triage the reports, and may follow up on various aspects identified.
Study NCT02715791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
Study NCT01439360 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A
Description: Intramuscular injection
Study NCT01439360 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix Junior
Description: Intramuscular injection administered to subjects aged 12 months or older
Study NCT01439360 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Intramuscular injection administered to subjects less than 12 months of age
Study NCT01439360 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax/ProVarivax
Description: Intramuscular injection administered to subjects more than 12 months of age
Study NCT01439360 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varilrix
Description: Subcutaneous injection administered to subjects more than 12 months of age
Study NCT06610292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reconciliation services
Description: Upon admission, information about patients Best Possible Medication History (BPMH) was extracted. Information on current medications, both regular and as-needed, was also recorded. All data were cross-referenced with the electronic records and verified through patients or caregivers interviews to create a comprehensive medication list.~Then, comparison was conducted between standard care medication list and Pharmacist-led medication reconciliation list to identify any possible medication discrepancies. Also, during hospital stay and upon discharge emerging medication discrepancies were assessed and resolved.~Moreover, the impacts on healthcare resources utilization within 30 days post-discharge was measured. This includes evaluating hospital re-admissions, emergency department visits, and the occurrence of any adverse drug events (ADEs).
Study NCT00812331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
Study NCT02199743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone
Description: Compare to haloperidol and perphenazine
Study NCT02199743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Compare to lurasidone
Study NCT02199743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: Compare to lurasidone
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO.
Study NCT03289429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
Study NCT03289429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
Study NCT03289429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous placebo
Description: 100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
Study NCT03289429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intravenous placebo
Description: 100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV or subcutaneously (SQ).
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Given IV.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Participants with mercaptopurine-related pancreatitis. Given PO.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given intramuscularly (IM).
Study NCT03289429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: tablets placebo
Description: Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
Study NCT03289429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tablets placebo
Description: Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
Study NCT01234077 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CPC M1
Description: CPC M1
Study NCT02877238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane plus remote ischemic preconditioning
Description: Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
Study NCT02877238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia plus remote ischemic preconditioning
Description: Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
Study NCT01319630 — intervention group
Intervention type: DEVICE
Intervention: Sidestream Dark Field (SDF)
Description: SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.~After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus.
Study NCT01319630 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy (NIRS)
Description: Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
Study NCT02455154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole endocrine therapy for 2.5mg qd po.
Study NCT02455154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole endocrine therapy for 2.5mg qd po.
Study NCT03117751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV.
Study NCT00003127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: 740 mg/m2 IV, Day 1, q 28 days X 6 cycles
Study NCT00003127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: target AUC=6, IV Day 1, q 28 days X 6 cycles
Study NCT00003127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2, IV, Day 1 q 28 days X 6 cycles
Study NCT01831024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dignicap System
Description: The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
Study NCT03729115 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Patients will have MRI scans every 6 months.
Study NCT00023959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given orally
Study NCT00023959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00023959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00023959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00023959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT00023959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03804840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication.
Study NCT03804840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04247139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir
Description: commercial versus traditional kefir
Study NCT02257138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT02257138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02257138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT02194387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Record dietary intake 4-7 days per week
Study NCT02194387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Record dietary intake 1 day per week
Study NCT02194387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive email coaching
Study NCT02194387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Participate in social networking
Study NCT02194387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02194387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02194387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone coaching
Study NCT02194387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text messages
Study NCT02939807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC294640
Description: ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days.
Study NCT02455154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zhongyaofufang
Description: Traditional Chinese Medicine for patients with Osteoporosis
Study NCT02455154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xianlinggubao
Description: Traditional Chinese Medicine for patients with Osteoporosis
Study NCT00563056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform
Study NCT00563056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flixotide plus Foradil
Study NCT01616966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Maintenance of anesthesia with sevoflurane 1.0 Vol%
Study NCT01616966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Maintenance of anesthesia with propofol
Study NCT01076478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol
Description: 100 mg, 200mg tablet Cilostazol
Study NCT01076478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: 100 mg, 200mg tablet Cilostazol
Study NCT03454763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT every 5 weeks
Description: PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
Study NCT03454763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRRT every 8-10 weeks
Description: PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
Study NCT04026113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
Study NCT04026113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT02732275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201 to be administered orally once daily in each 28-day cycle.
Study NCT02732275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
Study NCT04192565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColubrisMX Endoluminal Surgical (ELS) System
Description: Robotic Transanal Endoluminal Resection of Colorectal Lesions using the ColubrisMX Endoluminal Surgical (ELS) System
Study NCT03037931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: Intravenous Iron
Study NCT03037931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Solution
Study NCT04140019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMR
Description: Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
Study NCT04386291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Reduction Training
Description: Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.
Study NCT04386291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety Reduction Training
Description: Educational material will be provided every two weeks that address different aspects of anxiety and cognitive-behavioral approaches to reduce anxiety and stress.
Study NCT04556292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC10914
Description: SC10914 400mg tid
Study NCT00271960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CenteringPregnancy
Description: Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
Study NCT00271960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Description: Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
Study NCT00271960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancyPlus
Description: CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
Study NCT00271960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual prenatal care.
Study NCT02492022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic L008-1
Description: Dosing regimen of 2 capsules daily, once per day, for 14 weeks
Study NCT02492022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic L008-2
Description: Dosing regimen of 2 capsules daily, once per day, for 14 weeks
Study NCT02492022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing regimen of 2 capsules daily, once per day, for 14 weeks
Study NCT01015859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacing mode
Description: To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing